Orionis Biosciences

Foundation date

01/09/2015

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

We are an early stage drug discovery and development biotechnology company fueled by a suite of disruptive technologies to advance innovative medicines for the treatment of diseases with high unmet medical need – with an initial internal focus in oncology and immunotherapies.

Upcoming events

Latest news

  • argenx announces VYVGART (efgartigimod alfa) authorized for sale by Health Canada for generalized myasthenia gravis

    Thursday September 21st 2023

  • Galapagos appoints Simon Sturge to its Board of Directors

    Tuesday September 19th 2023

  • 13th Investment for HERAN Partners: Broken String Biosciences (UK)

    Tuesday September 19th 2023

Jobs by Orionis Biosciences